Please login to the form below

Not currently logged in
Email:
Password:

melanoma drug

This page shows the latest melanoma drug news and features for those working in and with pharma, biotech and healthcare.

Scancell preps phase 2 challenge for melanoma vaccine

Scancell preps phase 2 challenge for melanoma vaccine

Progress continues for biotech. Scancell says it is just weeks away from enrolling patients into its phase 2 trial of melanoma drug SCIB1, its lead T-cell boosting immunotherapy, in the ... The drug has already been through a phase 1/2 trial in around 35

Latest news

  • NICE turns down Opdivo for adjuvant melanoma therapy NICE turns down Opdivo for adjuvant melanoma therapy

    BMS drug currently only licensed treatment in this setting. Bristol-Myers Squibb’s efforts to push the use of Opdivo earlier in the course of melanoma treatment have hit a snag ... surveillance, which is usual current management for completely resected

  • Keytruda is first I-O drug cleared for melanoma in China Keytruda is first I-O drug cleared for melanoma in China

    The approval by the China National Drug Administration (CNDA) is for adults with unresectable or metastatic melanoma following failure of one prior line of therapy, and ends a drought in effective ... With the approval of pembrolizumab in China, the

  • BMS' Yervoy picks up another indication in Europe BMS' Yervoy picks up another indication in Europe

    The EU green light will be welcomed news after BMS saw the big-selling melanoma drug flop in a head-to-head trial with Merck &Co’s Keytruda (pembrolizumab), which was ... melanoma is an outcome of BMS’s unyielding commitment to advancing treatments

  • Novartis scores but Roche misses in melanoma trials Novartis scores but Roche misses in melanoma trials

    melanoma, but Roche was unable to match that in a trial of its Zelboraf candidate. ... indicates that the drugs could "transform the standard of care in the melanoma adjuvant setting".

  • BMS wins first US immuno-oncology paediatric licence BMS wins first US immuno-oncology paediatric licence

    The Food and Drug Administration (FDA) approved an expanded licence for Yervoy (ipilimumab) that will allow its use to treat unresectable or metastatic melanoma in patients aged 12 and older. ... led analysts at EvaluatePharma to predict that Merck

More from news
Approximately 2 fully matching, plus 69 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    But there are downsides too. It’s worth noting that Roche’s BRAF-targeting drug Zelboraf (vemurafenib) for melanoma has seen mixed results in other tumours, suggesting that ‘histologic context’ – ie ... While use of Imlygic has been limited,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment
Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....
Early diagnosis underpins NHS cancer strategy
Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan...

Infographics